SRSF1 induces glioma progression and has a potential diagnostic application in grading primary glioma

Ye,Li-Juan; Xu,Kai-Min; Bai,Gang; Yuan,Jing; Ran,Feng-Ming

doi:10.3892/ol.2023.13934

SRSF1 induces glioma progression and has a potential diagnostic application in grading primary glioma

Authors:
- Li-Juan Ye
- Kai-Min Xu
- Gang Bai
- Jing Yuan
- Feng-Ming Ran
View Affiliations

Affiliations: Department of Pathology, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital), Kunming, Yunnan 650118, P.R. China, Department of Neurosurgery, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital), Kunming, Yunnan 650118, P.R. China, Department of Pathology, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital), Kunming, Yunnan 650118, P.R. China
Published online on: June 28, 2023 https://doi.org/10.3892/ol.2023.13934
Article Number: 348
Copyright: © Ye et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioma is the most common intracranial tumor of the central nervous system in adults; however, the diagnosis of glioma, and its grading and histological subtyping, is challenging for pathologists. The present study assessed serine and arginine rich splicing factor 1 (SRSF1) expression in 224 glioma cases in the Chinese Glioma Genome Atlas (CGGA) database, and verified its expression by immunohistochemical analysis of specimens from 70 clinical patients. In addition, the prognostic potential of SRSF1 concerning the survival status of patients was evaluated. In vitro, the biological role of SRSF1 was assessed using MTT, colony formation, wound healing and Transwell assays. The results revealed that SRSF1 expression was significantly associated with the grading and the histopathological subtype of glioma. As determined using a receiver operating characteristic curve analysis, the specificity of SRSF1 for glioblastoma (GBM) and World Health Organization (WHO) grade 3 astrocytoma was 40 and 48%, respectively, whereas the sensitivity was 100 and 85%. By contrast, pilocytic astrocytoma tumors exhibited negative immunoexpression of SRSF1. Additionally, Kaplan‑Meier survival analysis indicated that high SRSF1 expression predicted a worse prognosis for patients with glioma in both the CGGA and clinical cohorts. In vitro, the results demonstrated that SRSF1 promoted the proliferation, invasion and migration of U87MG and U251 cells. These data suggested that immunohistochemical analysis of SRSF1 expression is highly sensitive and specific in the diagnosis of GBM and WHO grade 3 astrocytoma, and may have an important role in glioma grading. Furthermore, the lack of SRSF1 is a potential diagnostic biomarker for pilocytic astrocytoma. However, neither in oligodendroglioma and astrocytoma, nor in GBM was an association detected between SRSF1 expression and IDH1 mutations or 1p/19q co‑deletion. These findings indicated that SRSF1 may serve as a prognostic factor in glioma cases and could have an active role in promoting glioma progression.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Sanai N, Alvarez-Buylla A and Berger MS: Neural stem cells and the origin of gliomas. N Engl J Med. 353:811–822. 2005. View Article : Google Scholar : PubMed/NCBI
3	Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, et al: The 2021 WHO Classification of tumors of the central nervous system: A summary. Neuro Oncol. 23:1231–1251. 2021. View Article : Google Scholar : PubMed/NCBI
4	Sejda A, Grajkowska W, Trubicka J, Szutowicz E, Wojdacz T, Kloc W and Iżycka-Świeszewska E: WHO CNS5 2021 classification of gliomas: A practical review and road signs for diagnosing pathologists and proper patho-clinical and neuro-oncological cooperation. Folia Neuropathol. 60:137–152. 2022. View Article : Google Scholar : PubMed/NCBI
5	Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, et al: Glioma Groups Based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 372:2499–2508. 2015. View Article : Google Scholar : PubMed/NCBI
6	Louis DN, Wesseling P, Aldape K, Brat DJ, Capper D, Cree IA, Eberhart C, Figarella-Branger D, Fouladi M, Fuller GN, et al: cIMPACT-NOW update 6: New entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol. 30:844–856. 2020. View Article : Google Scholar : PubMed/NCBI
7	Davis ME: Epidemiology and overview of gliomas. Semin Oncol Nurs. 34:420–429. 2018. View Article : Google Scholar : PubMed/NCBI
8	Cáceres JF and Krainer AR: Functional analysis of pre-mRNA splicing factor SF2/ASF structural domains. EMBO J. 12:4715–4726. 1993. View Article : Google Scholar : PubMed/NCBI
9	Zuo P and Manley JL: Functional domains of the human splicing factor ASF/SF2. EMBO J. 12:4727–4737. 1993. View Article : Google Scholar : PubMed/NCBI
10	Das S and Krainer AR: Emerging functions of SRSF1, splicing factor and oncoprotein, in RNA metabolism and cancer. Mol Cancer Res. 12:1195–1204. 2014. View Article : Google Scholar : PubMed/NCBI
11	Paz S, Ritchie A, Mauer C and Caputi M: The RNA binding protein SRSF1 is a master switch of gene expression and regulation in the immune system. Cytokine Growth Factor Rev. 57:19–26. 2021. View Article : Google Scholar : PubMed/NCBI
12	Chen L, Luo C, Shen L, Liu Y, Wang Q, Zhang C, Guo R, Zhang Y, Xie Z, Wei N, et al: SRSF1 Prevents DNA damage and promotes tumorigenesis through regulation of DBF4B Pre-mRNA splicing. Cell Rep. 21:3406–3413. 2017. View Article : Google Scholar : PubMed/NCBI
13	Anczuków O, Rosenberg AZ, Akerman M, Das S, Zhan L, Karni R, Muthuswamy SK and Krainer AR: The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol. 19:220–228. 2012. View Article : Google Scholar : PubMed/NCBI
14	Lv Y, Zhang W, Zhao J, Sun B, Qi Y, Ji H, Chen C, Zhang J, Sheng J, Wang T, et al: SRSF1 inhibits autophagy through regulating Bcl-x splicing and interacting with PIK3C3 in lung cancer. Signal Transduct Target Ther. 6:1082021. View Article : Google Scholar : PubMed/NCBI
15	Das T, Lee EY, You HJ, Kim EE and Song EJ: USP15 and USP4 facilitate lung cancer cell proliferation by regulating the alternative splicing of SRSF1. Cell Death Discov. 8:242022. View Article : Google Scholar : PubMed/NCBI
16	Liu J, Yuan JF and Wang YZ: METTL3-stabilized lncRNA SNHG7 accelerates glycolysis in prostate cancer via SRSF1/c-Myc axis. Exp Cell Res. 416:1131492022. View Article : Google Scholar : PubMed/NCBI
17	Zhou X, Wang R, Li X, Yu L, Hua D, Sun C, Shi C, Luo W, Rao C, Jiang Z, et al: Splicing factor SRSF1 promotes gliomagenesis via oncogenic splice-switching of MYO1B. J Clin Invest. 129:676–693. 2019. View Article : Google Scholar : PubMed/NCBI
18	Broggi G, Barbagallo D, Lacarrubba F, Verzì AE, Micali G, Purrello M and Caltabiano R: The immunohistochemical expression of the serine and arginine-rich splicing factor 1 (SRSF1) is a predictive factor of the recurrence of basal cell carcinoma: A preliminary study on a series of 52 cases. Medicina (Kaunas). 58:1392022. View Article : Google Scholar : PubMed/NCBI
19	Brat DJ, Prayson RA, Ryken TC and Olson JJ: Diagnosis of malignant glioma: Role of neuropathology. J Neurooncol. 89:287–311. 2008. View Article : Google Scholar : PubMed/NCBI
20	Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, et al: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 18:170–186. 2021. View Article : Google Scholar : PubMed/NCBI
21	Broggi G, Salvatorelli L, Barbagallo D, Certo F, Altieri R, Tirrò E, Massimino M, Vigneri P, Guadagno E, Maugeri G, et al: Diagnostic utility of the immunohistochemical expression of serine and arginine rich splicing factor 1 (SRSF1) in the differential diagnosis of adult gliomas. Cancers (Basel). 13:20862021. View Article : Google Scholar : PubMed/NCBI
22	Wu J, Ni X, Yu Z, Wu S and Liu Z: CRNDE inducing cisplatin resistance through SRSF1/TIA1 signaling pathway in ovarian cancer. Pathol Res Pract. 235:1539572022. View Article : Google Scholar : PubMed/NCBI
23	Li J, Han T, Li Z, Han H, Yin Y, Zhang B, Zhang H and Li L: A Novel circRNA hsa_circRNA_002178 as a diagnostic marker in hepatocellular carcinoma enhances cell proliferation, invasion, and tumor growth by stabilizing SRSF1 expression. J Oncol. 2022:41840342022.PubMed/NCBI
24	Salifu SP and Doughan A: New clues to prognostic biomarkers of four hematological malignancies. J Cancer. 13:2490–2503. 2022. View Article : Google Scholar : PubMed/NCBI
25	Tejada S, Becerra-Castro MV, Nuñez-Cordoba J and Díez-Valle R: Ki-67 proliferative activity in the tumor margins as a robust prognosis factor in glioblastoma patients. J Neurol Surg A Cent Eur Neurosurg. 82:53–58. 2021. View Article : Google Scholar : PubMed/NCBI
26	Zhao A and Liu Y: Propofol suppresses colorectal cancer development by the circ-PABPN1/miR-638/SRSF1 axis. Anal Biochem. 631:1143542021. View Article : Google Scholar : PubMed/NCBI
27	Barbagallo D, Caponnetto A, Brex D, Mirabella F, Barbagallo C, Lauretta G, Morrone A, Certo F, Broggi G, Caltabiano R, et al: CircSMARCA5 Regulates VEGFA mRNA splicing and angiogenesis in glioblastoma multiforme through the binding of SRSF1. Cancers (Basel). 11:1942019. View Article : Google Scholar : PubMed/NCBI